Vertex Pharmaceuticals Stock

$459.41

0.05%

Nasdaq, Jul 07, 10:00 pm CET

ISIN

US92532F1003

Symbol

VRTX

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Vertex Pharmaceuticals Stock price

$459.41

+160.35 53.62% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.21 0.05%

ISIN

US92532F1003

Symbol

VRTX

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$118.0b

Enterprise Value

$111.9b

Net debt

positive

Cash

$6.2b

Shares outstanding

257.0m

Valuation (TTM | estimate)

P/E

negative | 25.1

P/S

10.6 | 9.7

EV/Sales

10.1 | 9.2

EV/FCF

negative

P/B

7.2

Financial Health

Equity Ratio

72.8%

Return on Equity

-3.3%

ROCE

22.0%

ROIC

87.5%

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$11.1b | $12.2b

EBITDA

$4.4b | $5.6b

EBIT

$4.2b | $5.4b

Net Income

$-988.9m | $4.7b

Free Cash Flow

$-1.3b

Growth (TTM | estimate)

Revenue

9.0% | 10.5%

EBITDA

-1.6% | 21.4%

EBIT

-1.8% | -

Net Income

-124.6% | 979.2%

Free Cash Flow

-136.2%

EPS

$-3.8

FCF per Share

$-4.9

Short interest

1.8%

Employees

Rev per Employee

$1.8m

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

40 Analysts have issued a Vertex Pharmaceuticals forecast:

24x Buy

60%

15x Hold

38%

More details on Analyst Estimates Including Price Targets

40 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy

60%

Hold

38%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	11,100 11,100	9% 9% 100%
- Direct Costs	1,551 1,551	16% 16% 14%
Gross Profit	9,549 9,549	8% 8% 86%
- Selling and Administrative Expenses	1,518 1,518	23% 23% 14%
- Research and Development Expense	3,821 3,821	13% 13% 34%
EBITDA	4,410 4,410	2% 2% 40%
- Depreciation and Amortization	202 202	3% 3% 2%
EBIT (Operating Income) EBIT	4,208 4,208	2% 2% 38%
Net Profit	-989 -989	125% 125% -9%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Vertex Pharmaceuticals Stock News

Positive

The Motley Fool

●

about 20 hours ago

3 No-Brainer Stocks to Buy in July

Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.

Neutral

The Motley Fool

●

3 days ago

The Best Stocks to Invest $1,000 In Right Now

Forget the market sell-off experienced earlier this year. Stocks are hot again.

Positive

Reuters

●

7 days ago

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office	United States
CEO	Reshma Kewalramani
Employees	6,100
Founded	1989
Website	www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now